SCHEMBL3880038

SCHEMBL3880038

COC(=O)c1cc(C(=O)C(N)=O)c2cc(Cc3ccc(F)cc3)cnc2c1O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
GRM2 Q14416 10/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSP90AA1 P07900 2/20 0.35
TP53 P04637 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
KDM5A P29375 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
PLA2G2A P14555 1/20 0.34
HSP90B1 P14625 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850748 0.92 GRM2 (0.42) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3866553 0.91 MAPT (0.41) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3869041 0.91 MAPT (0.41) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL13850851 0.91 MAPT (0.41) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3867478 0.89 MAPT (0.41) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3868863 0.89 MAPT (0.43) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3867709 0.89 MAPT (0.43) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3868008 0.88 MAPT (0.41) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3870135 0.88 MAPT (0.42) MAPTGRM2ALDH1A1HPGDKDM4E
SCHEMBL3866778 0.88 MAPT (0.42) MAPTGRM2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase MURAI HITOSHI 2009-05-07 US disclosed
EP-2045242-A1 Heterocyclic compounds having inhibitory activity against HIV integrase Shionogi&Co., Ltd. (JP) 2009-04-08 EP disclosed
US-7358249-B2 Heterocyclic compounds having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2008-04-15 US disclosed
US-20060247212-A1 Heterocyclic compounds having inhibitory activity against HIV integrase MURAI HITOSHI 2006-11-02 US disclosed
US-20060128669-A1 Heterocyclic compounds having inhibitory activity against hiv integrase SHIONOGI & CO., LTD. (JP) 2006-06-15 US disclosed
EP-1541558-A1 HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase CYP3A7, CDK7, CYP2A7 MAPT 4308/4885GRM2 4122/4885ALDH1A1 381/4885
US-20060247212-A1 Heterocyclic compounds having inhibitory activity against HIV integrase CYP3A7, CDK7, CYP2A7 MAPT 4304/4885GRM2 4144/4885ALDH1A1 370/4885
US-20060128669-A1 Heterocyclic compounds having inhibitory activity against hiv integrase CYP3A7, CDK7, CYP2A7 MAPT 4308/4885GRM2 4122/4885ALDH1A1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.